Slide 1: 2025 Annual Report
BioPorto 2025 Annual Report Carsten Buhl, CEO & Klaus Juhl Wulff, CFO March 26, 2026 CONFIDENTIAL | © Copyright BioPorto | 1
Slide 2: Forward-looking statements
Forward-looking statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte
Slide 3: Invest in AKI Diagnostic - Invest in BioPorto
Invest in AKI Diagnostic - Invest in BioPorto Early detection of AKI (Acute Kidney Injury) represents a major unmet need1 BioPorto’s ProNephro AKI (NGAL) is the first FDA-cleared test for pediatric AKI assessment Defined pathway for FDA approval and commercial launch of ProNephro AKI (NGAL) for adul
Slide 4: The "Forward" Strategic Plan
The ”Forward” Strategic Plan Focus on Execution of Market Access & Commercialization to transform kidney care Aspirations 1 Adoption +60 US Hospitals 2H 2027 Cash + Validation Study flow Positive 2026 High +100 Global Hospitals FY 2028 Revenue 2 Growth + Adult Indication 2027 150-200m DKK +170 Globa
Slide 5: Update Market Access – Adult Clinical Study
Update Market Access – Adult Clinical Study Pre-sub in process to be submitted to the FDA end of March 2026 Study designed to identifying adult FDA Clearance of Adult clinical study FDA Clearance patients at risk of developing will open an addressable market expected end 2027 moderate-to-severe acut
Slide 6: Update Commercialization – Health Economy
Update Commercialization – Health Economy Address an expensive condition and interrupt the cost curve related to AKI The magnitude of Why AKI is Why it matters & The value of NGAL the problem expensive what can be done biomarker $6bn Annual US Costs £1bn Annual UK Costs AKI is a high-volume, Costs e
Slide 7: +60 Hospitals by end of 2026 – Creating Adoption
+60 Hospitals by end of 2026 – Creating Adoption Expected Development of # of US Hospitals from 2024-2026 +36% +60 • Creating awareness and understanding; to create the future demand 22% 44 • NGAL Research Use Only (RUO) & continued focus on 36 the Pediatric segment • Focus on the market in North Am
Slide 8: Highlights of 2025
Highlights of 2025 A commercial milestone in the fourth quarter of 2025 was the availability of ProNephroTM AKI (NGAL) for the US market. At the end of October 2025, BioPorto successfully completed patient enrollment in its clinical cut-off study ProNephro AKI (NGAL) study for adult use. The three-y
Slide 9: NGAL Sales US continuing strong growth
NGAL Sales US continuing strong growth US NGAL RUO sales (accumulated 12 months rolling at constant exchange rates) 20 19 +29% 17,8 18 17 16,1 16 15,1 15 14,2 13,7 14 13,0 DKKm 13 12,3 11,8 12 11 10,2 10,1 10 8,7 9 7,9 8 7 6 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2
Slide 10: Continued NGAL growth in 2025 vs 2024
Continued NGAL growth in 2025 vs 2024 Revenue Q4 2025 vs Q4 2024, DKKm Revenue per quarter, DKKm FY 2025 vs 2024 US NGAL RUO +39% (+51%) Total revenue ROW NGAL +48% DKK 40.3m +11% (+13%) +47% ProNephro AKI (NGAL) +2.2m (+52%) 11,6 11,6 Total NGAL revenue +88% 10,6 10,4 (+96%) DKK 28.2m +22% (+25%) 9
Slide 11: Cost development year-over-year
Cost development year-over-year mDKK spend Increase in cost derived 60 from adult study 50 50 • Research & Development 40 spend increase by DKK 16 34 33 31 million, driven by the adult 30 30 27 clinical study. • Other operating cost were 20 in 2025 lower than 2024 10 - Sales & Marketing cost Reserar
Slide 12: Financial Guidance 2026
Financial Guidance 2026 Total NGAL Revenue Total Revenue Adjusted EBITDA loss DKK 33-42m DKK 48-58m DKK 50-60m (20-50%) (20-45%) CONFIDENTIAL | © Copyright BioPorto | 12
Slide 13: Q&A
Q&A